Skip Navigation

European Heart Journal 1986 7(7):546-559;
Copyright © 1986 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by HUGENHOLTZ, P.G.
Right arrow Articles by HÜLSMANN, W.C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HUGENHOLTZ, P.G.
Right arrow Articles by HÜLSMANN, W.C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1986 The European Society of Cardiology

On a possible role for calcium antagonists in atherosclerosis. A personal view

P.G. HUGENHOLTZ, P. LICHTLEN, W. VAN DER GlESSEN, A.E. BECKER, W.G. NAYLER, A. FLECKENSTEIN and W.C. HÜLSMANN

Thoraxcenter and Department of Biochemistry, Erasmus University Rotterdam The Netherlands and Medizinische Hochschule Hannover, Dept fur Innere Medizin Hannover Kleefeld, F.R.G.

Received 3 December 1985; revised 18 February 1986; .

Abstract

An overview is provided of current thinking regarding the origin(s) of atherosclerosis on the basis of clinical evidence, experimental models and pharmacological investigations with calcium antagonists. Because this group of drugs inhibits the influx of Ca2$ into the smooth muscle cell of the cardiovascular wall, it has been argued that when endothelial damage is anticipated or has occurred, the ‘protective’ action of calcium antagonists might avoid, delay or even help to repair the calcium overload seen with cell membrane damage. In the real world the situation must be far more complex as will become evident but as a concept the avoidance of Ca2$ overloading is enticing. In fact, based on circumstantial evidence, a major clinical trial is currently in progress in which the long term effect of nifedipine on coronary atherosclerosis is being evaluated in a double blind randomized fashion. The end-point of this study lies in the reduction of the severity and number of coronary artery lesions. Although not yet completed, the design and goals of that study are provided.

Key Words: Atherosclerosis, • calcium antagonists.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.